Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq:FBLG) received a USPTO Notice of Allowance for U.S. Patent Application No. 18/184,726 covering topical fibroblast spheroid therapy for wound healing. The 19 allowed claims address methods to treat and accelerate healing of wounds using 3D spheroid fibroblasts with or without fibroblast-derived materials.
The patent supports the ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers, a common chronic wound. Allowed claims specifically include topical treatment of chronic wounds and individuals with diabetes, closely matching FibroBiologics’ lead wound-healing program.
FibroBiologics (Nasdaq:FBLG) reported first patient dosing in its Phase 1/2 clinical trial of CYWC628 for diabetic foot ulcers during the week of June 1, 2026. The company is advancing CYWC628 manufacturing with a second GMP drug product run released for shipment to Australia and a third run underway.
FibroBiologics has completed the first two batches of its third GMP run, supporting ongoing trial supply and potential future clinical use.
FibroBiologics (Nasdaq:FBLG) announced first patients have been enrolled and dosed in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers. The randomized multicenter study in Australia will enroll up to 120 patients and compare topical CYWC628 plus standard of care to standard care alone.
Participants receive up to 12 weeks of treatment, with wound-healing outcomes and safety assessed regularly and an interim analysis after six weeks to evaluate primary safety and efficacy endpoints.
FibroBiologics (Nasdaq:FBLG) reported preclinical data for its psoriasis program CYPS317, using human dermal fibroblast (HDF) spheroids, presented at the 2026 Society for Investigative Dermatology meeting.
In psoriasis animal models, HDF spheroids reduced disease severity, prevented relapse, improved systemic safety versus single-cell HDFs, and showed targeted immunomodulation across key inflammatory pathways.
FibroBiologics (Nasdaq:FBLG) filed a new provisional patent application with the USPTO for oral fibroblast and fibroblast-derived therapeutics. The platform targets delivery to the gastrointestinal tract using encapsulation materials, hydrogels, nanoparticles, protective layers, and pH-sensitive coatings to preserve viability and enable targeted release.
The application covers whole fibroblast cells, spheroids, extracellular vesicles, fragments, conditioned media, and genetically modified variants, with potential use in chronic GI disorders such as inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, peptic ulcer disease, celiac disease, gastritis, and gastrointestinal cancers.
FibroBiologics (Nasdaq:FBLG) is expanding its fibroblast-based therapeutic platform to target Hantavirus pulmonary syndrome (HPS), building on preclinical work in acute respiratory distress syndrome (ARDS). HPS has >35–40% mortality and no approved antivirals.
The company is testing fibroblasts in Hantavirus models, focusing on inflammatory cytokine modulation, endothelial permeability, and tissue repair, and plans exploratory regulatory discussions toward potential clinical evaluation.
FibroBiologics (Nasdaq: FBLG) announced initiation of its clinical trial for lead program CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers. The company completed initial site activation and plans patient enrollment in Q2 2026 with topline data expected by end of 2026.
Management says its capital plan funds operations through the topline readout and highlights ongoing preclinical programs in multiple sclerosis, psoriasis, and an artificial thymus organoid platform.
FibroBiologics (Nasdaq: FBLG) reported preclinical burn-wound data on May 4, 2026 showing topical human dermal fibroblast (HDF) spheroids produced visible anti-inflammatory effects by day 8 and altered wound biomarkers.
Key findings include reduced inflammatory appearance across strains and sexes, ~3-fold lower IL1B and ~4-fold higher IL10 (p<0.01), and downward trends in collagen, ECM turnover, and myofibroblast activation genes.
FibroBiologics (Nasdaq: FBLG) announced on May 4, 2026 the release of the first cGMP batch of its investigational drug product CYWC628 to support a Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).
The batch was manufactured under cGMP and passed required safety and quality testing, enabling clinical use and positioning the company to begin patient enrollment for safety, tolerability, and preliminary efficacy evaluation.
FibroBiologics (Nasdaq: FBLG) reported Q1 2026 results and a corporate update on April 30, 2026. Key items: completed cGMP manufacture of initial CYWC628 batches, completed site onboarding, positive preclinical data in burn and degenerative disc programs, regained Nasdaq compliance, and raised capital via direct offerings.
Financials: R&D $3.0M, G&A $2.1M, net loss ~$5.0M, cash $1.5M at March 31, 2026; $2.5M net raised after quarter.